Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model - Kinkade, C W; Castillo-Martin, M; Puzio-Kuter, A; Yan, J; Foster, T H; Gao, H; Sun, Y; Ouyang, X; Gerald, W L; Cordon-Cardo, C; Abate-Shen, C (J Clin Invest, 2008)